Proteasome inhibition as novel treatment strategy in leukaemia

British Journal of Haematology

Volumn 134, Issue 3, 2006, Pages 253-262

  Vink, J ^a   Cloos, J ^a   Kaspers, G J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bortezomib; Leukaemia; Nuclear factor B; Proteasome; Proteasome inhibition

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ASPARAGINASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CELL PROTEIN; CEP 1612; CISPLATIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIHYDROEPONEMYCIN; DOCETAXEL; DOXORUBICIN; EPOXOMYCIN; FLUOROURACIL; GELDANAMYCIN; GEMCITABINE; IRINOTECAN; LACTACYSTIN; MELPHALAN; MG 262; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PS 273; TIPIFARNIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG EXPOSURE; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STEM CELL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I; FORECASTING; HUMANS; LEUKEMIA; NF-KAPPA B; PROTEASE INHIBITORS; PYRAZINES; UBIQUITIN;

EID: 33745621044     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06170.x     Document Type: Review

References (78)

1. Adams, J. (2002a) Development of the proteasome inhibitor PS-341. The Oncologist, 7, 9-16.
2. Adams, J. (2002b) Proteasome inhibitors as new anticancer drugs. Current Opinion in Oncology, 14, 628-634.
3. Adams, J. (2003a) The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews, 29(Suppl. 1), 3-9.
4. Adams, J. (2003b) Potential for proteasome inhibition in the treatment of cancer. Drug Discovery Today, 8, 307-315.
5. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417-421.
6. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L. & Stein, R.L. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic and Medicinal Chemistry Letters, 8, 333-338.
7. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
8. Adams, J., Palombella, V.J. & Elliott, P.J. (2000) Proteasome inhibition: a new strategy in cancer treatment. Investigational New Drugs, 18, 109-121.
9. Almond, J.B. & Cohen, G.M. (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia, 16, 433-443.
10. Appelbaum, F.R., Rowe, J.M., Radich, J. & Dick, J.E. (2001) Acute Myeloid Leukemia. Hematology/The Education Program of the American Society of Hematology, pp. 62-86.The American Society of Hematology, Washington, DC, USA.
11. Arrigo, A.P., Tanaka, K., Goldberg, A.L. & Welch, W.J. (1988) Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature, 331, 192-194.
12. Attar, E.C., De Angelo, D.J., Sirulnik, A., Wadleigh, M., Ballen, K.K., Miller, K.B., Galinsky, I., Neuberg, D., Trehu, E., Schenkein, D., Stone, R.M. & Amrein, P.C. (2005) Addition of bortezomib (Velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate. Blood, 106, 2782 (abstract).
13. Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell, 92, 367-380.
14. Beg, A.A. & Baltimore, D. (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science, 274, 782-784.
15. Birkenkamp, K.U., Geugien, M., Schepers, H., Westra, J., Lemmink, H.H. & Vellenga, E. (2004) Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia, 18, 103-112.
16. Boccadoro, M., Morgan, G. & Cavenagh, J. (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell International, 5, 18.
17. Bold, R.J., Virudachalam, S. & McConkey, D.J. (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. The Journal of Surgical Research, 100, 11-17.
18. Chandra, J., Niemer, I., Gilbreath, J., Kliche, K.O., Andreeff, M., Freireich, E.J., Keating, M. & McConkey, D.J. (1998) Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood, 92, 4220-4229.
19. Chauhan, D., Li, G., Auclair, D., Hideshima, T., Podar, K., Mitsiades, N., Mitsiades, C., Chen, L.B., Munshi, N., Saxena, S. & Anderson, K.C. (2004) 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock protein-27. Apoptosis, 9, 149-155.
20. Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Ruiz, S.L., Guerciolini, R., Wright, J. & Kantarjian, H. (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clinical Cancer Research, 10, 3371-3376.
21. Coux, O., Tanaka, K. & Goldberg, A.L. (1996) Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry, 65, 801-847.
22. Cusack, J.C. Jr, Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J. & Baldwin, A.S. Jr (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Research, 61, 3535-3540.
23. Dahlmann, B., Kopp, F., Kuehn, L., Niedel, B., Pfeifer, G., Hegerl, R. & Baumeister, W. (1989) The multicatalytic proteinase (prosome) is ubiquitous from eukaryotes to archaebacteria. FEBS Letters, 251, 125-131.
24. Dai, Y., Rahmani, M. & Grant, S. (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene, 22, 7108-7122.
25. Dai, Y., Rahmani, M., Pei, X.Y., Dent, P. & Grant, S. (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 104, 509-518.
26. Delic, J., Masdehors, P., Omura, S., Cosset, J.M., Dumont, J., Binet, J.L. & Magdelenat, H. (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radio-resistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. British Journal of Cancer, 77, 1103-1107.
27. Drexler, H.C. (1997) Activation of the cell death program by inhibition of proteasome function. Proceedings of the National Academy of Sciences of the United States of America, 94, 855-860.
28. Duechler, M., Linke, A., Cebula, B., Shehata, M., Schwarzmeier, J.D., Robak, T. & Smolewski, P. (2005) In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. European Journal of Haematology, 74, 407-417.
29. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J. & Schreiber, S.L. (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science, 268, 726-731.
30. Frankel, A., Man, S., Elliott, P., Adams, J. & Kerbel, R.S. (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical Cancer Research, 6, 3719-3728.
31. Fujioka, S., Schmidt, C., Sclabas, G.M., Li, Z., Pelicano, H., Peng, B., Yao, A., Niu, J., Zhang, W., Evans, D.B., Abbruzzese, J.L., Huang, P. & Chiao, P.J. (2004) Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. The Journal of Biological Chemistry, 279, 27549-27559.
32. Goldberg, A.L., Akopian, T.N., Kisselev, A.F., Lee, D.H. & Rohrwild, M. (1997) New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biological Chemistry, 378, 131-140.
33. Guan, Y., Gerhard, B. & Hogge, D.E. (2003) Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood, 101, 3142-3149.
34. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. & Jordan, C.T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301-2307.
35. Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilvassy, S.J. & Jordan, C.T. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 16220-16225.
36. Hershko, A. & Ciechanover, A. (1992) The ubiquitin system for protein degradation. Annual Review of Biochemistry, 61, 761-807.
37. Hershko, A. & Ciechanover, A. (1998) The ubiquitin system. Annual Review of Biochemistry, 67, 425-479.
38. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
39. Horton, T.M., Gannavarapu, A., Blaney, S.M., D'Argenio, D.Z., Plon, S.E. & Berg, S.L. (2006) Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology, 58, 13-23.
40. Kaspers, G.J. & Creutzig, U. (2005) Pediatric acute myeloid leukemia: international progress and future directions. Leukemia, 19, 2025-2029.
41. Kisselev, A.F. & Goldberg, A.L. (2001) Proteasome inhibitors: from research tools to drug candidates. Chemistry and Biology, 8, 739-758.
42. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S. & Ichihara, A. (1990) Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 87, 7071-7075.
43. Laport, G.F. & Larson, R.A. (1997) Treatment of adult acute lymphoblastic leukemia. Seminars in Oncology, 24, 70-82.
44. Lee, D.H. & Goldberg, A.L. (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends in Cell Biology, 8, 397-403.
45. Li, Q.Q., Yunmbam, M.K., Zhong, X., Yu, J.J., Mimnaugh, E.G., Neckers, L. & Reed, E. (2001) Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cellular and Molecular Biology (Noisy-le-Grand, France), 47, OL61-OL72 (online publication).
46. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
47. Masdehors, P., Omura, S., Merle-Beral, H., Mentz, F., Cosset, J.M., Dumont, J., Magdelenat, H. & Delic, J. (1999) Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. British Journal of Haematology, 105, 752-757.
48. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377.
49. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
50. Oikawa, T., Sasaki, T., Nakamura, M., Shimamura, M., Tanahashi, N., Omura, S. & Tanaka, K. (1998) The proteasome is involved in angiogenesis. Biochemical and Biophysical Research Communications, 246, 243-248.
51. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A., Grever, M.R., Orlowski, M. & Dang, C.V. (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Research, 58, 4342-4348.
52. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
53. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Van Deventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. & Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058-3065.
54. Pahler, J.C., Ruiz, S., Niemer, I., Calvert, L.R., Andreeff, M., Keating, M., Faderl, S. & McConkey, D.J. (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clinical Cancer Research, 9, 4570-4577.
55. Pervan, M., Pajonk, F., Sun, J.R., Withers, H.R. & McBride, W.H. (2001) Molecular pathways that modify tumor radiation response. American Journal of Clinical Oncology, 24, 481-485.
56. Pham, L.V., Tamayo, A.T., Yoshimura, L.C., Lo, P. & Ford, R.J. (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of Immunology, 171, 88-95.
57. Pui, C.H. & Evans, W.E. (1998) Acute lymphoblastic leukemia. The New England Journal of Medicine, 339, 605-615.
58. Richardson, P. (2003) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treatment Reviews, 29(Suppl. 1), 33-39.
59. Richardson, P.G., Hideshima, T. & Anderson, K.C. (2003a) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control, 10, 361-369.
60. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003b) A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine, 348, 2609-2617.
61. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 352, 2487-2498.
62. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. & Goldberg, A.L. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78, 761-771.
63. Romano, M.F., Lamberti, A., Turco, M.C. & Venuta, S. (2000) CD40 and B chronic lymphocytic leukemia cell response to fludarabine: the influence of NF-kappaB/Rel transcription factors on chemotherapy-induced apoptosis. Leukemia and Lymphoma, 36, 255-262.
64. Russo, S.M., Tepper, J.E., Baldwin, A.S. Jr, Liu, R., Adams, J., Elliott, P. & Cusack, J.C. Jr (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. International Journal of Radiation Oncology, Biology, Physics, 50, 183-193.
65. Schenkein, D. (2002) Proteasome inhibitors in the treatment of B-cell malignancies. Clinical Lymphoma, 3, 49-55.
66. Servida, F., Soligo, D., Delia, D., Henderson, C., Brancolini, C., Lombardi, L. & Deliliers, G.L. (2005) Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia, 19, 2324-2331.
67. Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R.A., Elliott, P.J., Adams, J. & Gallery, M.P. (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. Journal of Cellular Biochemistry, 82, 110-122.
68. Shimbara, N., Sato, C., Takashima, M., Tanaka, T., Tanaka, K. & Ichihara, A. (1993) Down-regulation of ubiquitin gene expression during differentiation of human leukemia cells. FEBS Letters, 322, 235-239.
69. Soligo, D., Servida, P., Delia, D., Fontanella, E., Lamorte, G., Caneva, L., Fumiatti, R. & Lambertenghi, D.G. (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. British Journal of Haematology, 113, 126-135.
70. Tan, C. & Waldmann, T.A. (2002) Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Research, 62, 1083-1086.
71. Chau, V., Tobias, J.W., Bachmair, A., Marriott, D., Ecker, D.J., Gonda, D.K. & Varshavsky, A. (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science, 243, 1576-1583.
72. Voorhees, P.M., Dees, E.G., O'Neil, B. & Orlowski, R.Z. (2003) The proteasome as a target for cancer therapy. Clinical Cancer Research, 9, 6316-6325.
73. Vrana, J.A. & Grant, S. (2001) Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood, 97, 2105-2114.
74. Wang, C.Y., Mayo, M.W. & Baldwin, A.S. Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science, 274, 784-787.
75. Yanamandra, N., Colaco, N.M., Parquet, N.A., Buzzeo, R.W., Boulware, D., Wright, G., Perez, L.E., Dalton, W.S. & Beaupre, D.M. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clinical Cancer Research, 12, 591-599.
76. Yu, J., Tiwari, S., Steiner, P. & Zhang, L. (2003) Differential apoptotic response to the proteasome inhibitor bortezomib [Velcade, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biology and Therapy, 2, 694-699.
77. Zhu, H., Zhang, L., Dong, F., Guo, W., Wu, S., Teraishi, F., Davis, J.J., Chiao, P.J. & Fang, B. (2005) Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene, 24, 4993-4999.
78. Zwickl, P., Voges, D. & Baumeister, W. (1999) The proteasome: a macromolecular assembly designed for controlled proteolysis. Philosophical Transactions of the Royal Society of London. Series B, Bio-logical Sciences, 354, 1501-1511.